Pembrolizumab in the Treatment of Patients with Advanced Urothelial Tract Cancer
Pembrolizumab is a humanized antibody that exerts dual blockade of the immune checkpoint receptor programmed death-1 (PD-1). It has demonstrated robust antitumor activity and acceptable tolerability in several tumors, including melanoma and lung cancer. The KEYNOTE-012 trial is an ongoing, [ Read More ]